Jedd D. Wolchok

Jedd Wolchok is a leading figure in cancer immunotherapy who has advanced combination checkpoint blockade strategies. His clinical trials combining CTLA-4 and PD-1 inhibitors demonstrated synergistic anti-tumor activity, establishing ipilimumab plus nivolumab as a standard regimen for metastatic melanoma. Wolchok continues to develop novel immunotherapy combinations and biomarker-guided treatment approaches.

Jedd Wolchok是癌症免疫治疗领域的领军人物，推进了联合检查点阻断策略。他结合CTLA-4和PD-1抑制剂的临床试验展示了协同抗肿瘤活性，确立了ipilimumab加nivolumab作为转移性黑色素瘤的标准方案。Wolchok继续开发新型免疫治疗组合和生物标志物指导的治疗方法。